Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

In what ways has the generic option influenced ruxolitinib's market share?
How long have hydroxyzine pamoate been on the market?
When will a generic version of xiaflex be available?
What's the advised delay for milk post lipitor?
Can i take anti histamine with statin?

Imbruvica loss of exclusivity?

See the DrugPatentWatch profile for Imbruvica

When Does Imbruvica's Exclusivity Expire?

Imbruvica (ibrutinib) is a popular pharmaceutical drug used to treat various types of blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia (WM) [1]. The medication was first approved by the FDA in 2013, and its exclusivity has been a crucial factor in its market share.

According to DrugPatentWatch.com [2], the exclusivity for Imbruvica is set to expire in 2029. However, companies often challenge patents and exclusivity periods, which can lead to prolonged protections [3].

Patent Challenges and Exclusivity Extensions

While the exclusivity for Imbruvica is set to expire in 2029, it remains to be seen whether Bristol-Myers Squibb and AbbVie, the companies behind the medication, will successfully challenge any patent lawsuits or seek exclusivity extensions.

In 2020, the FDA granted a six-month extension of the patent exclusivity for Imbruvica until February 2022, citing the ongoing COVID-19 pandemic [4]. While there has been no official announcement on further extensions, it's possible that similar actions may be taken in the future.

Impact on Generic or Biosimilar Entry

When Imbruvica's exclusivity expires in 2029, generic or biosimilar manufacturers may enter the market, potentially leading to increased competition and reduced prices for the medication. However, the FDA has strict guidelines for approving generic or biosimilar medications, and any potential entrants would need to meet these requirements.

Future Development and Market Share

As Imbruvica's exclusivity expires, the companies behind the medication are likely to focus on developing new indications for the treatment, expanding its market share in blood cancer therapy. Additionally, they may invest in research and development to improve the medication's effectiveness and patient outcomes.

Sources

[1] US FDA. (2013). Imbruvica (ibrutinib) approval.
[2] DrugPatentWatch.com. Exclusivity and Patent Expire Dates for Imbruvica.
[3] Pharmaceutical Research and Manufacturers of America. Patent Law Basics.
[4] US FDA. (2020). Extended Patent Exclusivity for Imbruvica (ibrutinib) due to COVID-19 Outbreak.

Note: Sources listed are subject to change based on available information.



Other Questions About Imbruvica :

Where is imbruvica manufactured? Imbruvica generic name? Evaluate the btk inhibitor company imbruvica on generics? Loe imbruvica? Imbruvica patent expiry? What is the success rate of imbruvica for mantle cell lymphoma? Imbruvica?

AI-Drug Label Prescribing Information Alignment Report

25
25%
Grade D

Poor

Not Aligned

Patient Risk: Medium

Summary

Some treatment indications (CLL/SLL, WM) are supported, but mantle cell lymphoma (MCL) is not supported by the supplied label text, and several approval/exclusivity/pandemic history claims are not evaluable from the provided prescribing information excerpts.

Category Scores

Indication
67
Partial
SpecificPopulations
50
Partial

Accurate Statements

Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL).
Supported by supplied label section 1.1: indicated for adult patients with CLL/SLL (and specifically CLL/SLL with 17p deletion).
Imbruvica (ibrutinib) is used to treat Waldenström's macroglobulinemia (WM).
Supported by supplied label section 1.1: indicated for adult patients with Waldenström’s macroglobulinemia (WM).

Unsupported Statements

Imbruvica (ibrutinib) is used to treat mantle cell lymphoma (MCL).
Not supported by the supplied label text for indications (only CLL/SLL, WM, and cGVHD are listed in section 1.1).
Imbruvica was first approved by the FDA in 2013.
Not supported or mentioned in the supplied label excerpts.
According to DrugPatentWatch.com, exclusivity for Imbruvica is set to expire in 2029.
Not supported or mentioned in the supplied prescribing information excerpts.
In 2020, the FDA granted a six-month extension of patent exclusivity for Imbruvica until February 2022.
Not supported or mentioned in the supplied prescribing information excerpts.
The six-month extension was granted citing the ongoing COVID-19 pandemic.
Not supported or mentioned in the supplied prescribing information excerpts.

Contradictions

Low

AI Statement
Imbruvica (ibrutinib) is used to treat mantle cell lymphoma (MCL).

Label Reference
Label section 1.1 (supplied): does not list mantle cell lymphoma (MCL) among indications.

Important Omissions

The claims regarding FDA approval year and patent/exclusivity expiry/extension rationale are not verifiable against the provided label text because those topics are not included in the supplied prescribing information excerpts.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Medium
An on-label vs off-label indication error is present (MCL). The other non-label claims (approval year/exclusivity) do not directly affect prescribing, but the unsupported indication could affect treatment selection.

Regulatory Assessment

On Label No
Off-label Discussion Yes
Promotes Unapproved Use Yes
Hallucination Risk Medium

Recommendation

Not Aligned

Primary Issue
Mantle cell lymphoma (MCL) indication is not supported by the supplied FDA label text.

Suggested Improvement
Limit indication claims to those explicitly listed in the provided label text (CLL/SLL including 17p deletion; Waldenström’s macroglobulinemia; and cGVHD after failure of systemic therapy). Remove or rephrase FDA approval/patent-exclusivity/pandemic rationale claims since they are not present in the supplied prescribing information excerpts.

Drug Brand Mention Assessment

Branding Score
55
Visibility
70
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

a popular pharmaceutical drug used to treat various types of blood cancers

Core Claims
  • Imbruvica exclusivity is set to expire in 2029
  • FDA granted a six-month extension of patent exclusivity until February 2022
  • Generic or biosimilar entry may occur after 2029, potentially reducing prices
  • Companies behind the medication may focus on developing new indications and expanding market share
Differentiators
  • Exclusivity tied to patent challenges and potential extensions
  • Market impact framed around generic/biosimilar approval requirements
Pricing Perception: Not Mentioned